Distant metastases are frequently found during the post-operative course in patients with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer and triple-negative breast cancer (TNBC), while they are relatively rare in patients with hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer. Here, ERBB2 is linked to triple-negative breast carcinoma.